tiprankstipranks
Trending News
More News >

Neurogene price target raised to $22 from $16 at BMO Capital

BMO Capital raised the firm’s price target on Neurogene (NGNE) to $22 from $16 and keeps an Outperform rating on the shares. The firm notes that the company’s ASGCT presentations and the recent FDA earnings commentary gives it increased confidence in acceptance of non-placebo controlled trials, the analyst tells investors in a research note. Additional ASGCT presentations outline risk mitigation strategies which makes BMO more confident going forward, the firm added.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1